Methylation changes and pathways affected in preterm birth: a role for SLC6A3 in neurodevelopment

Area of Science:

• Epigenetics
• Neonatal Medicine
• Developmental Biology

Background:

• Preterm birth is associated with increased risks of neurodevelopmental disorders.
• Epigenetic modifications, such as DNA methylation, play a crucial role in gene regulation and development.
• Understanding methylation differences in preterm infants may offer insights into early biomarkers for neurodevelopmental outcomes.

Purpose of the Study:

• To investigate differential DNA methylation patterns in white blood cells of preterm versus full-term newborns.
• To identify specific genes or CpG sites associated with prematurity and potential neurodevelopmental implications.

Main Methods:

• A cohort of preterm (n=24) and full-term (n=22) newborns was recruited.
• Anthropometrical and biochemical features were assessed at 12 months of corrected gestational age.
• DNA methylation levels were analyzed, and neurodevelopment was evaluated using the Bayley Scale of Infant Development at 24-36 months.

Main Results:

• Significant differences in DNA methylation levels were observed between preterm and full-term newborns.
• The cg00997378 CpG site within the SLC6A3 gene showed the most pronounced methylation differences (p < 0.0001).
• SLC6A3 methylation levels were associated with prematurity risk factors.

Conclusions:

• DNA methylation patterns in white blood cells differ between preterm and full-term newborns.
• SLC6A3 methylation may serve as a potential epigenetic biomarker for early diagnosis and management of neurodevelopmental diseases in newborns.
• Further research into SLC6A3 methylation could inform interventions for neurodevelopmental disorders in infants born prematurely.